{"transactions":[{"id":4634616,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50579,"kind":"person","name":"Lerner Neil","position":1,"cik":"0001505148","reported_name":"Lerner Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-10-02T16:00:24.000Z","date":"2026-10-01","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.92,"value":18400.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"62,500 of the shares represents unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":420000,"source":{"system":"sec-edgar","filing":"0001171843-26-006349","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326006349/ownership.xml","form_type":"4"}},{"id":4626652,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50579,"kind":"person","name":"Lerner Neil","position":1,"cik":"0001505148","reported_name":"Lerner Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-09-25T12:01:13.000Z","date":"2026-09-24","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":1.14,"value":2850.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"62,500 of the shares represents unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":400000,"source":{"system":"sec-edgar","filing":"0001171843-26-006235","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326006235/ownership.xml","form_type":"4"}},{"id":796900,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50579,"kind":"person","name":"Lerner Neil","position":1,"cik":"0001505148","reported_name":"Lerner Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-04-30T20:00:48.000Z","date":"2026-04-29","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":1.89,"value":28350.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"62,500 of the shares represents unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":397500,"source":{"system":"sec-edgar","filing":"0001171843-26-002894","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326002894/ownership.xml","form_type":"4/A","original_submission_date":"2026-04-29"}},{"id":797127,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50621,"kind":"person","name":"Anderman Jonathan","position":1,"cik":"0002032625","reported_name":"Anderman Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-04-30T16:00:25.000Z","date":"2026-04-29","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":1.89,"value":47250.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"150,000 of the shares represents unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":196000,"source":{"system":"sec-edgar","filing":"0001171843-26-002893","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032625/000117184326002893/ownership.xml","form_type":"4/A","original_submission_date":"2026-04-29"}},{"id":798098,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50621,"kind":"person","name":"Anderman Jonathan","position":1,"cik":"0002032625","reported_name":"Anderman Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-04-29T21:11:59.000Z","date":"2026-04-29","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":1.89,"value":47250.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"150,000 of the shares represents unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":196000,"source":{"system":"sec-edgar","filing":"0001171843-26-002840","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032625/000117184326002840/ownership.xml","form_type":"4"}},{"id":797963,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50579,"kind":"person","name":"Lerner Neil","position":1,"cik":"0001505148","reported_name":"Lerner Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-04-29T20:58:36.000Z","date":"2026-04-29","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":1.89,"value":28350.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"62,500 of the shares represents unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":397500,"source":{"system":"sec-edgar","filing":"0001171843-26-002834","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326002834/ownership.xml","form_type":"4"}},{"id":912082,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-02-10T13:00:15.000Z","date":"2026-02-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":36687,"price":6.52,"value":239199.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"125,000 of the shares represent unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":6603336,"source":{"system":"sec-edgar","filing":"0001171843-26-000722","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000722/ownership.xml","form_type":"4"}},{"id":941059,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-01-12T13:00:13.000Z","date":"2026-01-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":46777,"price":5.35,"value":250256.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"250,000 of the shares represent unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":6640023,"source":{"system":"sec-edgar","filing":"0001171843-26-000205","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000205/ownership.xml","form_type":"4"}},{"id":951654,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:33:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over 48 substantially equal monthly installments starting February 2, 2026."}],"balance_after":2000000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001171843-26-000060","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000060/ownership.xml","form_type":"4"}},{"id":951653,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-01-05T21:33:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":5.17,"value":1292500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"250,000 of the shares represent unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":6686800,"source":{"system":"sec-edgar","filing":"0001171843-26-000060","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000060/ownership.xml","form_type":"4"}},{"id":951655,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70328,"kind":"person","name":"Prasad Arjun","position":1,"cik":"0002102138","reported_name":"Prasad Arjun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2026-01-05T21:33:32.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":1000000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"COMMON STOCK","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001171843-26-000059","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000059/ownership.xml","form_type":"4"}},{"id":951651,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":39613,"kind":"person","name":"LINDAHL RICHARD S","position":1,"cik":"0001196632","reported_name":"LINDAHL RICHARD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:33:21.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders."}],"balance_after":90000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001171843-26-000058","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000058/ownership.xml","form_type":"4"}},{"id":951652,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70329,"kind":"person","name":"Chiniara Ellen","position":1,"cik":"0001398764","reported_name":"Chiniara Ellen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:33:04.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders."}],"balance_after":90000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001171843-26-000057","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000057/ownership.xml","form_type":"4"}},{"id":951650,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50579,"kind":"person","name":"Lerner Neil","position":1,"cik":"0001505148","reported_name":"Lerner Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:32:59.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":435000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over 48 substantially equal monthly installments starting February 2, 2026."}],"balance_after":435000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":435000},"source":{"system":"sec-edgar","filing":"0001171843-26-000056","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000056/ownership.xml","form_type":"4"}},{"id":951649,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50579,"kind":"person","name":"Lerner Neil","position":1,"cik":"0001505148","reported_name":"Lerner Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:32:59.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":5.17,"value":323125.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"62,500 of the shares represents unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":382500,"source":{"system":"sec-edgar","filing":"0001171843-26-000056","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000056/ownership.xml","form_type":"4"}},{"id":951647,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:32:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders."}],"balance_after":90000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001171843-26-000055","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000055/ownership.xml","form_type":"4"}},{"id":951648,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:32:36.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Enavate Sciences, LP (\"Enavate\"). Pursuant to an agreement with Enavate, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to Enavate, which will in turn ensure that such securities or economic benefits are provided to Enavate"}],"balance_after":90000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001171843-26-000054","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000054/ownership.xml","form_type":"4"}},{"id":951646,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:32:19.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). Pursuant to an agreement with OrbiMed Advisors, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and OrbiMed Capital GP V LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V-KA, LP."}],"balance_after":90000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001171843-26-000053","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000053/ownership.xml","form_type":"4"}},{"id":952272,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50621,"kind":"person","name":"Anderman Jonathan","position":1,"cik":"0002032625","reported_name":"Anderman Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:32:06.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":720000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over 48 substantially equal monthly installments starting February 2, 2026."}],"balance_after":720000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":720000},"source":{"system":"sec-edgar","filing":"0001171843-26-000051","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2032625/000117184326000051/ownership.xml","form_type":"4"}},{"id":952271,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50621,"kind":"person","name":"Anderman Jonathan","position":1,"cik":"0002032625","reported_name":"Anderman Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-01-05T21:32:06.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":5.17,"value":775500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"150,000 of the shares represents unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":171000,"source":{"system":"sec-edgar","filing":"0001171843-26-000051","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032625/000117184326000051/ownership.xml","form_type":"4"}},{"id":951723,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70332,"kind":"person","name":"Shin Barry","position":1,"cik":"0001780448","reported_name":"Shin Barry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T16:33:59.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":670000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over 48 substantially equal monthly installments starting February 2, 2026."}],"balance_after":670000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":670000},"source":{"system":"sec-edgar","filing":"0001171843-26-000062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1780448/000117184326000062/ownership.xml","form_type":"4"}},{"id":951722,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70332,"kind":"person","name":"Shin Barry","position":1,"cik":"0001780448","reported_name":"Shin Barry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2026-01-05T16:33:59.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":5.17,"value":646250.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"300,000 of the shares represents unvested restricted stock units (\"RSU\") granted on December 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on December 9, 2025. 125,000 of the shares represents unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":525000,"source":{"system":"sec-edgar","filing":"0001171843-26-000062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1780448/000117184326000062/ownership.xml","form_type":"4"}},{"id":951769,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70336,"kind":"person","name":"Sirard Cynthia","position":1,"cik":"0001808408","reported_name":"Sirard Cynthia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2026-01-05T16:33:55.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":1000000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"COMMON STOCK","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001171843-26-000061","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808408/000117184326000061/ownership.xml","form_type":"4"}},{"id":951790,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70338,"kind":"person","name":"Ferneau Philip","position":1,"cik":"0001814202","reported_name":"Ferneau Philip","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T16:32:09.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant vests in full upon the earlier of (i) June 10, 2026 and (ii) the date of the next annual meeting of the Company's stockholders."}],"balance_after":90000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001171843-26-000052","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814202/000117184326000052/ownership.xml","form_type":"4"}},{"id":995846,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-18T13:30:51.000Z","date":"2025-11-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":44025,"price":4.83,"value":212640.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"250,000 of the shares represent unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":6436800,"source":{"system":"sec-edgar","filing":"0001171843-25-007400","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325007400/ownership.xml","form_type":"4"}},{"id":1133470,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-05-27T19:24:21.000Z","date":"2025-05-27","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.11,"value":21100.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in two transactions at prices of $2.105 and $2.115 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"150,000 of the shares represent unvested RSUs granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 250,000 of the shares represent unvested RSUs granted on February 8, 2023. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested RSUs granted on January 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":6480825,"source":{"system":"sec-edgar","filing":"0001171843-25-003462","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325003462/ownership.xml","form_type":"4"}},{"id":1173308,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T23:37:43.000Z","date":"2025-04-09","kind":"sale","planned":false,"acquired":false,"shares":3571428,"price":1.59,"value":5678570.52,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V, OrbiMed Advisors, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V, OrbiMed Advisors, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-25-000385","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000094787125000385/ownership.xml","form_type":"4"}},{"id":1173563,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T23:24:24.000Z","date":"2025-04-09","kind":"sale","planned":false,"acquired":false,"shares":3571428,"price":1.59,"value":5678570.52,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-25-000384","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000384/ownership.xml","form_type":"4"}},{"id":1175811,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50621,"kind":"person","name":"Anderman Jonathan","position":1,"cik":"0002032625","reported_name":"Anderman Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Gen Counsel & Corporate Sec"}}],"security":"Common Stock","published_at":"2025-04-08T13:30:55.000Z","date":"2025-04-07","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":1.54,"value":30800.0,"ownership":{"direct":true},"balance_after":21000,"source":{"system":"sec-edgar","filing":"0001171843-25-002086","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032625/000117184325002086/ownership.xml","form_type":"4"}},{"id":1175654,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50579,"kind":"person","name":"Lerner Neil","position":1,"cik":"0001505148","reported_name":"Lerner Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-04-08T13:25:57.000Z","date":"2025-04-07","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":1.42,"value":28400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.43 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."}],"balance_after":320000,"source":{"system":"sec-edgar","filing":"0001171843-25-002084","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325002084/ownership.xml","form_type":"4"}},{"id":1269704,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T22:12:03.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."}],"balance_after":1500000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"CommonStock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001171843-25-000831","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000831/ownership.xml","form_type":"4"}},{"id":1269705,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":39613,"kind":"person","name":"LINDAHL RICHARD S","position":1,"cik":"0001196632","reported_name":"LINDAHL RICHARD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T22:11:36.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."}],"balance_after":40000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-25-000830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000830/ownership.xml","form_type":"4"}},{"id":1269703,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50579,"kind":"person","name":"Lerner Neil","position":1,"cik":"0001505148","reported_name":"Lerner Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CAO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T22:11:11.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."}],"balance_after":200000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001171843-25-000829","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000829/ownership.xml","form_type":"4"}},{"id":1269702,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T22:10:43.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."}],"balance_after":40000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-25-000828","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000828/ownership.xml","form_type":"4"}},{"id":1269701,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70329,"kind":"person","name":"Chiniara Ellen","position":1,"cik":"0001398764","reported_name":"Chiniara Ellen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T22:09:52.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."}],"balance_after":40000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-25-000826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000826/ownership.xml","form_type":"4"}},{"id":1269922,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50621,"kind":"person","name":"Anderman Jonathan","position":1,"cik":"0002032625","reported_name":"Anderman Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP, Gen Counsel & Corp Sec"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T22:09:27.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."}],"balance_after":280000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001171843-25-000825","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032625/000117184325000825/ownership.xml","form_type":"4"}},{"id":1269700,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T22:08:58.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). Pursuant to an agreement with OrbiMed Advisors, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and OrbiMed Capital GP V LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V-KA, LP."}],"balance_after":40000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-25-000824","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000824/ownership.xml","form_type":"4"}},{"id":1269699,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T22:05:34.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Enavate Sciences, LP (\"Enavate\"). Pursuant to an agreement with Enavate, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to Enavate, which will in turn ensure that such securities or economic benefits are provided to Enavate."}],"balance_after":40000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-25-000823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000823/ownership.xml","form_type":"4"}},{"id":1269714,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70332,"kind":"person","name":"Shin Barry","position":1,"cik":"0001780448","reported_name":"Shin Barry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T17:12:31.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."}],"balance_after":250000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001171843-25-000832","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1780448/000117184325000832/ownership.xml","form_type":"4"}},{"id":1269731,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70338,"kind":"person","name":"Ferneau Philip","position":1,"cik":"0001814202","reported_name":"Ferneau Philip","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T17:10:18.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."}],"balance_after":40000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-25-000827","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814202/000117184325000827/ownership.xml","form_type":"4"}},{"id":1274068,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-02-11T15:37:49.000Z","date":"2025-02-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":41687,"price":3.5,"value":145904.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"125,000 of the shares represent unvested RSUs granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 250,000 of the shares represent unvested RSUs granted on February 8, 2023. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested RSUs granted on January 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":6470825,"source":{"system":"sec-edgar","filing":"0001171843-25-000735","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000735/ownership.xml","form_type":"4"}},{"id":1304344,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-01-13T13:30:10.000Z","date":"2025-01-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":58054,"price":1.86,"value":107980.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"150,000 of the shares represent unvested RSUs granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 375,000 of the shares represent unvested RSUs granted on February 8, 2023. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested RSUs granted on January 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":6512512,"source":{"system":"sec-edgar","filing":"0001171843-25-000195","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000195/ownership.xml","form_type":"4"}},{"id":1337277,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70332,"kind":"person","name":"Shin Barry","position":1,"cik":"0001780448","reported_name":"Shin Barry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-10T14:02:28.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on December 9, 2025, with the remaining over 36 substantially equal monthly installments starting January 9, 2026."}],"balance_after":400000,"derivative":{"exercise_price":1.65,"expiration_date":"2034-12-09","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001171843-24-006859","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1780448/000117184324006859/ownership.xml","form_type":"4"}},{"id":1337276,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70332,"kind":"person","name":"Shin Barry","position":1,"cik":"0001780448","reported_name":"Shin Barry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2024-12-10T14:02:28.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":1.65,"value":660000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted to the reporting person on December 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on December 9, 2025."}],"balance_after":400000,"source":{"system":"sec-edgar","filing":"0001171843-24-006859","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1780448/000117184324006859/ownership.xml","form_type":"4"}},{"id":1433988,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":50621,"kind":"person","name":"Anderman Jonathan","position":1,"cik":"0002032625","reported_name":"Anderman Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP, Gen Counsel & Corp Sec"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-14T12:49:46.000Z","date":"2024-08-13","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting September 13, 2024."}],"balance_after":300000,"derivative":{"exercise_price":1.2,"expiration_date":"2034-08-13","underlying":"CommonStock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001171843-24-004782","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032625/000117184324004782/ownership.xml","form_type":"4"}},{"id":1584287,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-11T14:12:03.000Z","date":"2024-03-08","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting April 8, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Enavate Sciences, LP (\"Enavate\"). Pursuant to an agreement with Enavate, the Reporting Person has agreed to receive and hold for the benefit of Enavate any securities issued under any stock options or other awards granted to him for his services as a director on the Issuer's board of directors. As such, the Reporting Person disclaims beneficial ownership of, and all right, title and interest in, the reported securities."}],"balance_after":40000,"derivative":{"exercise_price":1.96,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-24-001275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324001275/ownership.xml","form_type":"4"}},{"id":1643245,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-14T17:03:56.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 9, 2024."}],"balance_after":40000,"derivative":{"exercise_price":1.57,"expiration_date":"2034-02-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-24-000796","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000796/ownership.xml","form_type":"4"}},{"id":1643244,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":39613,"kind":"person","name":"LINDAHL RICHARD S","position":1,"cik":"0001196632","reported_name":"LINDAHL RICHARD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-14T17:03:16.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 9, 2024."}],"balance_after":40000,"derivative":{"exercise_price":1.57,"expiration_date":"2034-02-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-24-000795","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000795/ownership.xml","form_type":"4"}},{"id":1643243,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-14T17:02:15.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 9, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). Pursuant to an agreement with OrbiMed Advisors, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and OrbiMed Capital GP V LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V-KA, LP."}],"balance_after":40000,"derivative":{"exercise_price":1.57,"expiration_date":"2034-02-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-24-000794","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000794/ownership.xml","form_type":"4"}},{"id":1643242,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70329,"kind":"person","name":"Chiniara Ellen","position":1,"cik":"0001398764","reported_name":"Chiniara Ellen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-14T17:01:10.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 9, 2024."}],"balance_after":40000,"derivative":{"exercise_price":1.57,"expiration_date":"2034-02-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-24-000793","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000793/ownership.xml","form_type":"4"}},{"id":1643373,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70338,"kind":"person","name":"Ferneau Philip","position":1,"cik":"0001814202","reported_name":"Ferneau Philip","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-14T12:00:18.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 9, 2024."}],"balance_after":40000,"derivative":{"exercise_price":1.57,"expiration_date":"2034-02-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-24-000792","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814202/000117184324000792/ownership.xml","form_type":"4"}},{"id":1651650,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT"}}],"security":"Common Stock","published_at":"2024-02-09T17:49:22.000Z","date":"2024-02-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":44782,"price":1.45,"value":64933.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"300,000 of the shares represents unvested restricted stock units (\"RSU\") granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 16, 2022. 375,000 of the shares represents unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 637,500 of the shares represents unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":6570566,"source":{"system":"sec-edgar","filing":"0001171843-24-000714","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000714/ownership.xml","form_type":"4"}},{"id":1652324,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":94472,"kind":"person","name":"Bisker-Leib Vered","position":1,"cik":"0001814093","reported_name":"Bisker-Leib Vered","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-02-09T12:50:39.000Z","date":"2024-02-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":49198,"price":1.45,"value":71337.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"300,000 of the shares represents unvested restricted stock units (\"RSU\") granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 16, 2022. 300,000 of the shares represents unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 1,753,125 of the shares represents unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":3124426,"source":{"system":"sec-edgar","filing":"0001171843-24-000715","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814093/000117184324000715/ownership.xml","form_type":"4"}},{"id":1681640,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-10T15:31:08.000Z","date":"2024-01-09","kind":"grant","planned":false,"acquired":true,"shares":637500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over 48 substantially equal monthly installments starting February 9, 2024."}],"balance_after":637500,"derivative":{"exercise_price":1.93,"expiration_date":"2034-01-08","underlying":"CommonStock","underlying_shares":637500},"source":{"system":"sec-edgar","filing":"0001171843-24-000178","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000178/ownership.xml","form_type":"4"}},{"id":1681639,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R&D"}}],"security":"Common Stock","published_at":"2024-01-10T15:31:08.000Z","date":"2024-01-09","kind":"grant","planned":false,"acquired":true,"shares":637500,"price":1.93,"value":1230375.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted to the reporting person on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on January 9, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"300,000 of the shares represents unvested restricted stock units (\"RSU\") granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 500,000 of the shares represents unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 637,500 of the shares represents unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":6615348,"source":{"system":"sec-edgar","filing":"0001171843-24-000178","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000178/ownership.xml","form_type":"4"}},{"id":1682022,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":94472,"kind":"person","name":"Bisker-Leib Vered","position":1,"cik":"0001814093","reported_name":"Bisker-Leib Vered","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-10T10:31:46.000Z","date":"2024-01-09","kind":"grant","planned":false,"acquired":true,"shares":1753125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over 48 substantially equal monthly installments starting February 9, 2024."}],"balance_after":1753125,"derivative":{"exercise_price":1.93,"expiration_date":"2034-01-08","underlying":"CommonStock","underlying_shares":1753125},"source":{"system":"sec-edgar","filing":"0001171843-24-000179","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814093/000117184324000179/ownership.xml","form_type":"4"}},{"id":1682021,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":94472,"kind":"person","name":"Bisker-Leib Vered","position":1,"cik":"0001814093","reported_name":"Bisker-Leib Vered","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-10T10:31:46.000Z","date":"2024-01-09","kind":"grant","planned":false,"acquired":true,"shares":1753125,"price":1.93,"value":3383531.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted to the reporting person on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on January 9, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"300,000 of the shares represents unvested restricted stock units (\"RSU\") granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 400,000 of the shares represents unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 1,753,125 of the shares represents unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":3173624,"source":{"system":"sec-edgar","filing":"0001171843-24-000179","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814093/000117184324000179/ownership.xml","form_type":"4"}},{"id":1732765,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-11-21T19:08:42.000Z","date":"2023-11-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":44025,"price":1.5,"value":66037.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"12,222 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which will vest on November 30 and December 31, 2023. 300,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":5977848,"source":{"system":"sec-edgar","filing":"0001171843-23-007222","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323007222/ownership.xml","form_type":"4"}},{"id":1733672,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":94472,"kind":"person","name":"Bisker-Leib Vered","position":1,"cik":"0001814093","reported_name":"Bisker-Leib Vered","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-11-21T14:10:51.000Z","date":"2023-11-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":64415,"price":1.5,"value":96622.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"8,148 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which will vest on November 30 and December 31, 2023. 300,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. 400,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":1420499,"source":{"system":"sec-edgar","filing":"0001171843-23-007223","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814093/000117184323007223/ownership.xml","form_type":"4"}},{"id":1914933,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":39613,"kind":"person","name":"LINDAHL RICHARD S","position":1,"cik":"0001196632","reported_name":"LINDAHL RICHARD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-24T20:32:59.000Z","date":"2023-04-21","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting May 21, 2023."}],"balance_after":50000,"derivative":{"exercise_price":2.91,"expiration_date":"2033-04-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001171843-23-002483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323002483/ownership.xml","form_type":"4"}},{"id":1958876,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-03-10T18:34:51.000Z","date":"2023-03-10","kind":"purchase","acquired":true,"shares":10000,"price":3.37,"value":33700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.30 to $3.40 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"89,051 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 27,937 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 61,114 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":6021873,"source":{"system":"sec-edgar","filing":"0001171843-23-001588","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323001588/ownership.xml","form_type":"4"}},{"id":1990520,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-02-27T16:39:07.000Z","date":"2023-02-27","kind":"purchase","acquired":true,"shares":20000,"price":3.98,"value":79600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.97 to $3.98 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"100,751 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 33,525 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 67,226 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":6011873,"source":{"system":"sec-edgar","filing":"0001171843-23-001175","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323001175/ownership.xml","form_type":"4"}},{"id":2013679,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-02-15T15:47:57.000Z","date":"2023-02-15","kind":"purchase","acquired":true,"shares":20000,"price":3.86,"value":77200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.76 to $3.89 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"100,751 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 33,525 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 67,226 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":5991873,"source":{"system":"sec-edgar","filing":"0001171843-23-000974","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000974/ownership.xml","form_type":"4"}},{"id":2022806,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":117050,"kind":"person","name":"WURZER DAVID M","position":1,"cik":"0001207118","reported_name":"WURZER DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-10T21:01:30.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 8, 2023."}],"balance_after":50000,"derivative":{"exercise_price":3.93,"expiration_date":"2033-02-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001171843-23-000901","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000901/ownership.xml","form_type":"4"}},{"id":2024831,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70329,"kind":"person","name":"Chiniara Ellen","position":1,"cik":"0001398764","reported_name":"Chiniara Ellen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-09T21:31:41.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 8, 2023."}],"balance_after":40000,"derivative":{"exercise_price":3.93,"expiration_date":"2033-02-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-23-000855","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000855/ownership.xml","form_type":"4"}},{"id":2024830,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-09T21:31:05.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 8, 2023."}],"balance_after":40000,"derivative":{"exercise_price":3.93,"expiration_date":"2033-02-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-23-000854","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000854/ownership.xml","form_type":"4"}},{"id":2024829,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-09T21:28:25.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 8, 2023."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). Pursuant to an agreement with OrbiMed Advisors, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and OrbiMed Capital GP V LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V-KA, LP."}],"balance_after":60000,"derivative":{"exercise_price":3.93,"expiration_date":"2033-02-07","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001171843-23-000852","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000852/ownership.xml","form_type":"4"}},{"id":2024820,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-09T21:23:48.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over 48 substantially equal monthly installments starting March 8, 2023."}],"balance_after":700000,"derivative":{"exercise_price":3.93,"expiration_date":"2033-02-07","underlying":"CommonStock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001171843-23-000851","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000851/ownership.xml","form_type":"4"}},{"id":2024819,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-02-09T21:23:48.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on February 8, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"100,751 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 33,525 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 67,226 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":5971873,"source":{"system":"sec-edgar","filing":"0001171843-23-000851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000851/ownership.xml","form_type":"4"}},{"id":2024904,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":70338,"kind":"person","name":"Ferneau Philip","position":1,"cik":"0001814202","reported_name":"Ferneau Philip","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-09T16:28:25.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 8, 2023."}],"balance_after":50000,"derivative":{"exercise_price":3.93,"expiration_date":"2033-02-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001171843-23-000853","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814202/000117184323000853/ownership.xml","form_type":"4"}},{"id":2025611,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":94472,"kind":"person","name":"Bisker-Leib Vered","position":1,"cik":"0001814093","reported_name":"Bisker-Leib Vered","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-09T15:03:07.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over 48 substantially equal monthly installments starting March 8, 2023."}],"balance_after":600000,"derivative":{"exercise_price":3.93,"expiration_date":"2033-02-07","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001171843-23-000846","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814093/000117184323000846/ownership.xml","form_type":"4"}},{"id":2025610,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":94472,"kind":"person","name":"Bisker-Leib Vered","position":1,"cik":"0001814093","reported_name":"Bisker-Leib Vered","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-02-09T15:03:07.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on February 8, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"60,981 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 16,163 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 44,818 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. 400,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":1484914,"source":{"system":"sec-edgar","filing":"0001171843-23-000846","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814093/000117184323000846/ownership.xml","form_type":"4"}},{"id":2040398,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-01-31T15:14:18.000Z","date":"2023-01-31","kind":"purchase","acquired":true,"shares":20000,"price":4.05,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"112,449 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 39,112 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 73,337 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":5471873,"source":{"system":"sec-edgar","filing":"0001171843-23-000557","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000557/ownership.xml","form_type":"4"}},{"id":2047526,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-01-24T15:49:22.000Z","date":"2023-01-24","kind":"purchase","acquired":true,"shares":20000,"price":4.19,"value":83800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.07 to $4.33 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"112,449 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 39,112 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 73,337 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":5451873,"source":{"system":"sec-edgar","filing":"0001171843-23-000419","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000419/ownership.xml","form_type":"4"}},{"id":2104664,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":94472,"kind":"person","name":"Bisker-Leib Vered","position":1,"cik":"0001814093","reported_name":"Bisker-Leib Vered","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-25T16:41:02.000Z","date":"2022-11-25","kind":"sale","acquired":false,"shares":2,"price":4.36,"value":8.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are included in the Reporting Person's award agreement which allows the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."}],"balance_after":1060414,"source":{"system":"sec-edgar","filing":"0001171843-22-007662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814093/000117184322007662/ownership.xml","form_type":"4"}},{"id":2104663,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":94472,"kind":"person","name":"Bisker-Leib Vered","position":1,"cik":"0001814093","reported_name":"Bisker-Leib Vered","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-25T16:41:02.000Z","date":"2022-11-23","kind":"sale","acquired":false,"shares":9569,"price":4.3,"value":41146.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are included in the Reporting Person's award agreement which allows the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.10 to $4.30 per share on November 22, 2022 and $4.15 to $4.43 on November 23, 2022. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."}],"balance_after":1060416,"source":{"system":"sec-edgar","filing":"0001171843-22-007662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814093/000117184322007662/ownership.xml","form_type":"4"}},{"id":2104662,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":94472,"kind":"person","name":"Bisker-Leib Vered","position":1,"cik":"0001814093","reported_name":"Bisker-Leib Vered","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-25T16:41:02.000Z","date":"2022-11-22","kind":"sale","acquired":false,"shares":14929,"price":4.19,"value":62552.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are included in the Reporting Person's award agreement which allows the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.10 to $4.30 per share on November 22, 2022 and $4.15 to $4.43 on November 23, 2022. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."}],"balance_after":1069985,"source":{"system":"sec-edgar","filing":"0001171843-22-007662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814093/000117184322007662/ownership.xml","form_type":"4"}},{"id":2107761,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":94472,"kind":"person","name":"Bisker-Leib Vered","position":1,"cik":"0001814093","reported_name":"Bisker-Leib Vered","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-22T16:15:49.000Z","date":"2022-11-21","kind":"sale","acquired":false,"shares":16035,"price":4.34,"value":69591.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are included in the Reporting Person's award agreement which allows the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.31 to $4.49 per share on November 18, 2022 and $4.30 to $4.44 on November 21, 2022. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."}],"balance_after":1084914,"source":{"system":"sec-edgar","filing":"0001171843-22-007635","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814093/000117184322007635/ownership.xml","form_type":"4"}},{"id":2107760,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":94472,"kind":"person","name":"Bisker-Leib Vered","position":1,"cik":"0001814093","reported_name":"Bisker-Leib Vered","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-22T16:15:49.000Z","date":"2022-11-18","kind":"sale","acquired":false,"shares":6226,"price":4.4,"value":27394.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are included in the Reporting Person's award agreement which allows the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.31 to $4.49 per share on November 18, 2022 and $4.30 to $4.44 on November 21, 2022. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."}],"balance_after":1107175,"source":{"system":"sec-edgar","filing":"0001171843-22-007635","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814093/000117184322007635/ownership.xml","form_type":"4"}},{"id":2120274,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-10T21:44:21.000Z","date":"2022-11-08","kind":"purchase","acquired":true,"shares":402000,"price":3.21,"value":1290420.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by GP V, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":15219994,"source":{"system":"sec-edgar","filing":"0000947871-22-001164","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122001164/ownership.xml","form_type":"4"}},{"id":2120101,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-10T21:38:57.000Z","date":"2022-11-08","kind":"purchase","acquired":true,"shares":402000,"price":3.21,"value":1290420.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, GP V, OrbiMed Advisors, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V, OrbiMed Advisors, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":15219994,"source":{"system":"sec-edgar","filing":"0000947871-22-001163","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000094787122001163/ownership.xml","form_type":"4"}},{"id":2149974,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-09-28T20:45:33.000Z","date":"2022-09-28","kind":"purchase","acquired":true,"shares":10000,"price":2.32,"value":23200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.30 to $2.33 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"159,246 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 61,462 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 97,784 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5431873,"source":{"system":"sec-edgar","filing":"0001171843-22-006282","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322006282/ownership.xml","form_type":"4"}},{"id":2150557,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-09-27T13:47:18.000Z","date":"2022-09-26","kind":"purchase","acquired":true,"shares":15000,"price":2.27,"value":34050.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.24 to $2.28 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"159,246 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 61,462 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 97,784 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5421873,"source":{"system":"sec-edgar","filing":"0001171843-22-006243","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322006243/ownership.xml","form_type":"4"}},{"id":2163178,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-09-08T14:12:23.000Z","date":"2022-09-07","kind":"purchase","acquired":true,"shares":15000,"price":3.03,"value":45450.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.02 to $3.04 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"159,246 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 61,462 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 97,784 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5406873,"source":{"system":"sec-edgar","filing":"0001171843-22-006005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322006005/ownership.xml","form_type":"4"}},{"id":2169019,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-09-01T18:37:05.000Z","date":"2022-09-01","kind":"purchase","acquired":true,"shares":15000,"price":2.83,"value":42450.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.77 to $2.89 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"159,246 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 61,462 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 97,784 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5391873,"source":{"system":"sec-edgar","filing":"0001171843-22-005905","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322005905/ownership.xml","form_type":"4"}},{"id":2181843,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-08-17T20:06:55.000Z","date":"2022-08-17","kind":"purchase","acquired":true,"shares":15000,"price":3.05,"value":45750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"170,946 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 67,050 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 103,896 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5376873,"source":{"system":"sec-edgar","filing":"0001171843-22-005700","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322005700/ownership.xml","form_type":"4"}},{"id":2189557,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-08-10T14:51:32.000Z","date":"2022-08-10","kind":"purchase","acquired":true,"shares":15000,"price":2.64,"value":39600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.57 to $2.75 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"170,946 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 67,050 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 103,896 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5361873,"source":{"system":"sec-edgar","filing":"0001171843-22-005567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322005567/ownership.xml","form_type":"4"}},{"id":2197737,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-08-02T13:15:40.000Z","date":"2022-08-01","kind":"purchase","acquired":true,"shares":15000,"price":2.58,"value":38700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.51 to $2.62 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"170,946 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 67,050 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 103,896 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5346873,"source":{"system":"sec-edgar","filing":"0001171843-22-005231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322005231/ownership.xml","form_type":"4"}},{"id":2225500,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-06-21T17:41:46.000Z","date":"2022-06-21","kind":"purchase","acquired":true,"shares":20000,"price":2.8,"value":56000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.78 to $2.81 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5331873,"source":{"system":"sec-edgar","filing":"0001171843-22-004440","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322004440/ownership.xml","form_type":"4"}},{"id":2228018,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-06-17T20:46:45.000Z","date":"2022-06-16","kind":"purchase","acquired":true,"shares":20000,"price":2.34,"value":46800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.31 to $2.40 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5311873,"source":{"system":"sec-edgar","filing":"0001171843-22-004408","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322004408/ownership.xml","form_type":"4"}},{"id":2234232,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-06-13T19:59:22.000Z","date":"2022-06-13","kind":"purchase","acquired":true,"shares":30000,"price":2.29,"value":68700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.20 to $2.31 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5291873,"source":{"system":"sec-edgar","filing":"0001171843-22-004327","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322004327/ownership.xml","form_type":"4"}},{"id":2240285,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-06-07T15:50:59.000Z","date":"2022-06-06","kind":"purchase","acquired":true,"shares":30000,"price":2.83,"value":84900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.82 to $2.87 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5261873,"source":{"system":"sec-edgar","filing":"0001171843-22-004190","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322004190/ownership.xml","form_type":"4"}},{"id":2249595,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-06-01T16:33:27.000Z","date":"2022-06-01","kind":"purchase","acquired":true,"shares":20000,"price":3.03,"value":60600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.94 to $3.08 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5231873,"source":{"system":"sec-edgar","filing":"0001171843-22-004068","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322004068/ownership.xml","form_type":"4"}},{"id":2255325,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-05-26T18:58:01.000Z","date":"2022-05-26","kind":"purchase","acquired":true,"shares":20000,"price":3.04,"value":60800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.98 to $3.07 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"206,043 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 83,812 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 122,231 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5211873,"source":{"system":"sec-edgar","filing":"0001171843-22-003978","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322003978/ownership.xml","form_type":"4"}},{"id":2258395,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-05-24T12:09:42.000Z","date":"2022-05-23","kind":"purchase","acquired":true,"shares":18355,"price":2.72,"value":49925.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.51 to $2.89 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"206,043 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 83,812 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 122,231 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5191873,"source":{"system":"sec-edgar","filing":"0001171843-22-003899","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322003899/ownership.xml","form_type":"4"}},{"id":2268261,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-05-17T19:17:04.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":20215,"price":2.47,"value":49931.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.45 to $2.50 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"206,043 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 83,812 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 122,231 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5173518,"source":{"system":"sec-edgar","filing":"0001171843-22-003771","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322003771/ownership.xml","form_type":"4"}},{"id":2272142,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T21:48:49.000Z","date":"2022-05-13","kind":"purchase","acquired":true,"shares":30722,"price":2.49,"value":76497.78,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These Shares were purchased in multiple transactions at prices ranging from $2.46 to $2.54. The price reported reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of the Reporting Person, GP V, OrbiMed Advisors, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V, OrbiMed Advisors, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14817994,"source":{"system":"sec-edgar","filing":"0000947871-22-000568","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000094787122000568/ownership.xml","form_type":"4"}},{"id":2272141,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T21:48:49.000Z","date":"2022-05-12","kind":"purchase","acquired":true,"shares":97094,"price":2.35,"value":228170.9,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These Shares were purchased in multiple transactions at prices ranging from $2.22 to $2.46. The price reported reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of the Reporting Person, GP V, OrbiMed Advisors, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V, OrbiMed Advisors, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14787272,"source":{"system":"sec-edgar","filing":"0000947871-22-000568","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000094787122000568/ownership.xml","form_type":"4"}},{"id":2272140,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T21:48:49.000Z","date":"2022-05-11","kind":"purchase","acquired":true,"shares":64700,"price":1.79,"value":115813.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in multiple transactions at prices ranging from $1.79 to $1.80. The price reported reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of the Reporting Person, GP V, OrbiMed Advisors, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V, OrbiMed Advisors, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14690178,"source":{"system":"sec-edgar","filing":"0000947871-22-000568","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000094787122000568/ownership.xml","form_type":"4"}},{"id":2272465,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T21:45:38.000Z","date":"2022-05-13","kind":"purchase","acquired":true,"shares":30722,"price":2.49,"value":76497.78,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These Shares were purchased in multiple transactions at prices ranging from $2.46 to $2.54. The price reported reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by GP V, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14817994,"source":{"system":"sec-edgar","filing":"0000947871-22-000567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000567/ownership.xml","form_type":"4"}}],"next_cursor":"2022-05-13T21:45:38.000000Z,2272465"}